Screener
Immunovant, Inc. IMVT Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Immunovant, Inc.’s 10-Q, filed February 6, 2026.
- Filed
- Feb 6, 2026, 7:24 AM EST
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q4 2025
- Accession
- 0001764013-26-000011
| Line item | Nine Months Ended December 31, 2025 | Nine Months Ended December 31, 2024 |
|---|---|---|
| Proceeds from stock options exercised | 48,508 | 3,880 |
| Net cash provided by financing activities | 592,116 | 3,880 |
| Effect of exchange rate changes on cash and cash equivalents | 689 | 1,235 |
| Net change in cash and cash equivalents | 280,554 | (260,680) |
| Cash and cash equivalents – beginning of period | 713,971 | 635,365 |
| Cash and cash equivalents – end of period | $994,525 | $374,685 |
| Non-cash operating activity | ||
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | $73 | — |
Item 1. Financial Statements (unaudited)
FAQ
- What is Immunovant, Inc.'s net change in cash?
- Immunovant, Inc. (IMVT) reported net change in cash of $472.66M in Q4 2025.
- How has Immunovant, Inc.'s net change in cash changed year-over-year?
- Immunovant, Inc.'s net change in cash increased by 581.0% year-over-year, from -$98.26M to $472.66M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Immunovant, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude